KR20220132588A - 탈최적화된 SARS-CoV-2 및 이의 방법 및 용도 - Google Patents

탈최적화된 SARS-CoV-2 및 이의 방법 및 용도 Download PDF

Info

Publication number
KR20220132588A
KR20220132588A KR1020227029265A KR20227029265A KR20220132588A KR 20220132588 A KR20220132588 A KR 20220132588A KR 1020227029265 A KR1020227029265 A KR 1020227029265A KR 20227029265 A KR20227029265 A KR 20227029265A KR 20220132588 A KR20220132588 A KR 20220132588A
Authority
KR
South Korea
Prior art keywords
cov
sars
coronavirus
polynucleotide
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227029265A
Other languages
English (en)
Korean (ko)
Inventor
슈테펜 뮐러
존 로버트 콜먼
잉 왕
첸 양
Original Assignee
코다제닉스 인코포레이티드
세럼 인스티튜트 오브 인디아 프라이비트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코다제닉스 인코포레이티드, 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 filed Critical 코다제닉스 인코포레이티드
Publication of KR20220132588A publication Critical patent/KR20220132588A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
KR1020227029265A 2020-01-28 2021-01-27 탈최적화된 SARS-CoV-2 및 이의 방법 및 용도 Pending KR20220132588A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US62/966,750 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US63/048,942 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US63/079,337 2020-09-16
US202063079853P 2020-09-17 2020-09-17
US63/079,853 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (1)

Publication Number Publication Date
KR20220132588A true KR20220132588A (ko) 2022-09-30

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029265A Pending KR20220132588A (ko) 2020-01-28 2021-01-27 탈최적화된 SARS-CoV-2 및 이의 방법 및 용도

Country Status (17)

Country Link
US (1) US20230117167A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096712A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023519640A (cg-RX-API-DMAC7.html)
KR (1) KR20220132588A (cg-RX-API-DMAC7.html)
CN (1) CN115427073A (cg-RX-API-DMAC7.html)
AU (1) AU2021213121A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014700A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168100A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002030A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010743A2 (cg-RX-API-DMAC7.html)
IL (1) IL295112A (cg-RX-API-DMAC7.html)
MX (1) MX2022009099A (cg-RX-API-DMAC7.html)
PE (1) PE20230166A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551788A1 (cg-RX-API-DMAC7.html)
SA (1) SA522433428B1 (cg-RX-API-DMAC7.html)
TW (1) TW202144570A (cg-RX-API-DMAC7.html)
WO (1) WO2021154828A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
MX2022009688A (es) * 2020-02-07 2022-12-15 Rnaimmune Inc Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus.
WO2021177773A2 (ko) * 2020-03-06 2021-09-10 (주)지노믹트리 Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법
WO2022011428A1 (en) * 2020-07-16 2022-01-20 Griffith University Live-attenuated virus vaccine
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
TW202328166A (zh) 2021-08-11 2023-07-16 美商達冕生物有限公司 針對新型冠狀病毒感染之mRNA疫苗之組成物及方法
CN115704013A (zh) * 2021-08-13 2023-02-17 北京化工大学 一种冠状病毒致弱突变株及其制备方法和应用
US20250057939A1 (en) 2021-09-08 2025-02-20 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
US20250295756A1 (en) * 2022-01-20 2025-09-25 Freie Universität Berlin Live attenuated sars-cov-2 and a vaccine made thereof
KR20240163164A (ko) * 2022-03-28 2024-11-18 유니버시태트 베른 원-투-스톱(One-to-stop) 약독화된 SARS-CoV-2 바이러스
KR20250060275A (ko) 2022-09-05 2025-05-07 프라이 유니베르시탯 베를린 살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
JP2025534031A (ja) * 2022-10-12 2025-10-09 ウニヴェルズィテート ベルン ワントゥーストップ(one-to-stop)弱毒化SARS-CoV-2ウイルスによる治療
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024097259A1 (en) 2022-11-01 2024-05-10 RNAimmune, Inc. Composition and methods for mrna vaccines against novel omicron coronavirus infections
WO2025081050A1 (en) * 2023-10-13 2025-04-17 Duke University Coronavirus stem helix and fusion peptide nanoparticle vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
EP2808384B1 (en) * 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
PL2139515T5 (pl) * 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
US20120269849A1 (en) * 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
CN104072592B (zh) * 2013-03-26 2016-12-28 复旦大学 对新型冠状病毒HCoV-EMC 2012感染具有抑制作用的多肽及其应用
KR20180085802A (ko) * 2015-12-11 2018-07-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Ns1 및 ns2 유전자 이동을 포함하는 재조합 rsv 균주
CN110506060B (zh) * 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
US20200299651A1 (en) * 2017-10-16 2020-09-24 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine

Also Published As

Publication number Publication date
CL2022002030A1 (es) 2023-03-10
PH12022551788A1 (en) 2024-02-26
US20230117167A1 (en) 2023-04-20
CO2022010743A2 (es) 2022-08-30
MX2022009099A (es) 2022-10-20
CA3168100A1 (en) 2021-08-05
EP4096712A4 (en) 2024-05-08
SA522433428B1 (ar) 2024-10-08
CN115427073A (zh) 2022-12-02
PE20230166A1 (es) 2023-02-01
JP2023519640A (ja) 2023-05-11
WO2021154828A1 (en) 2021-08-05
EP4096712A1 (en) 2022-12-07
AU2021213121A1 (en) 2022-08-18
TW202144570A (zh) 2021-12-01
BR112022014700A2 (pt) 2022-10-11
IL295112A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CN115427073A (zh) 去优化SARS-CoV-2及其方法和用途
US20220378904A1 (en) Hmpv mrna vaccine composition
US20230338506A1 (en) Respiratory virus immunizing compositions
WO2021222304A1 (en) Sars-cov-2 rna vaccines
US20210046173A1 (en) Rsv rna vaccines
WO2021159130A2 (en) Coronavirus rna vaccines and methods of use
KR20170098871A (ko) 페스티바이러스
WO2021208913A1 (zh) 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用
JP2022507053A (ja) 新規ブタロタウイルス
JP6538071B2 (ja) 非天然発生のブタ生殖器呼吸器症候群ウイルス(prrsv)及び使用する方法
US20240299533A1 (en) Deoptimized sars-cov-2 variants and methods and uses thereof
KR20220009960A (ko) 재조합 고전적 돼지 열병 바이러스
US11090384B2 (en) Arthrogenic alphavirus vaccine
EP2571519B1 (en) Marker vaccine for classical swine fever
CN115666633A (zh) CpG-佐剂的SARS-CoV-2病毒疫苗
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
CN100398155C (zh) 用于预防反刍动物捻转血矛线虫病的dna疫苗
HK40095771A (en) NOVEL CORONAVIRUS mRNA VACCINE AGAINST MUTANT STRAINS
HK40112103A (en) Alphavirus vectors containing universal cloning adaptors
CN115851621A (zh) 一种重组狂犬病病毒疫苗株及其制备方法
CN117210496A (zh) 一种新型冠状病毒的免疫原及其应用
HK40060584B (en) Recombinant classical swine fever virus
CN120676963A (zh) 使用一至终止减毒的SARS-CoV-2病毒的治疗

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240129

Comment text: Request for Examination of Application